In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Digital biomarkers offer major potential, yet the pathway from research to real‑world use remains complex. TNO and Orikami are closing this gap by combining scientific validation with a certified, ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Predictive biomarkers to guide selection of first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) are an unmet clinical need. This study used the Computational Histology ...

The integration of proteomics in biomarker discovery represents a major advancement in molecular diagnostics and precision medicine. Researchers seek highly specific indicators of complex disease ...

Biomarkers can offer critical information about an individual’s health status, disease prognosis or how they might respond to a treatment. Developments in high-throughput technologies that enable the ...

Functional biomarkers are objective measurements that reflect the process and progression of a disease, and the effect of drug intervention. They enable everything from earlier, more accurate disease ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...